Literature DB >> 12908467

Oncology's trials.

Bruce Booth1, Robert Glassman, Philip Ma.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12908467     DOI： 10.1038/nrd1158

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

2.  Do molecularly targeted agents in oncology have reduced attrition rates?

Authors:  Ian Walker; Herbie Newell
Journal:  Nat Rev Drug Discov       Date:  2008-11-14       Impact factor: 84.694

Review 3.  Molecular networks in drug discovery.

Authors:  John Kenneth Morrow; Longzhang Tian; Shuxing Zhang
Journal:  Crit Rev Biomed Eng       Date:  2010

4.  A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.

Authors:  John R Goffin; Greg R Pond; Dongsheng Tu
Journal:  BMC Med Res Methodol       Date:  2011-06-21       Impact factor: 4.615

5.  Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

Authors:  John R Goffin; Greg R Pond
Journal:  BMC Med Res Methodol       Date:  2011-12-12       Impact factor: 4.615

6.  Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.

Authors:  Marco A De Velasco; Hirotsugu Uemura
Journal:  Adv Urol       Date:  2012-02-21

7.  Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells.

Authors:  Aaron Chen; Eugene Lee; Roger Tu; Kevin Santiago; Anna Grosberg; Charless Fowlkes; Michelle Khine
Journal:  Biomaterials       Date:  2013-10-18       Impact factor: 15.304

Review 8.  A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

Authors:  Michael J Grayling; Munyaradzi Dimairo; Adrian P Mander; Thomas F Jaki
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

9.  A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.

Authors:  Daniel D Von Hoff; Gary M Clark; Charles A Coltman; Mary L Disis; S G Eckhardt; Lee M Ellis; Margaret Foti; Elizabeth Garrett-Mayer; Mithat Gönen; Manuel Hidalgo; Susan G Hilsenbeck; John H Littlefield; Patricia M LoRusso; H Kim Lyerly; Neal J Meropol; Jyoti D Patel; Steven Piantadosi; Dean A Post; Meredith M Regan; Yu Shyr; Margaret A Tempero; Joel E Tepper; Jamie Von Roenn; Louis M Weiner; Donn C Young; Nu V Vu
Journal:  Clin Cancer Res       Date:  2021-07-26       Impact factor: 12.531

Review 10.  Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.

Authors:  Ian R Powley; Meeta Patel; Gareth Miles; Howard Pringle; Lynne Howells; Anne Thomas; Catherine Kettleborough; Justin Bryans; Tim Hammonds; Marion MacFarlane; Catrin Pritchard
Journal:  Br J Cancer       Date:  2020-01-02       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.